FcγRIIB regulates autoantibody responses by limiting marginal zone B cell activation.
Level 5 - mechanism / opinion, no new human data
Mechanistic animal knockout model and human ex vivo observational comparison
PubMed 35819855 · doi:10.1172/JCI157250
What was done
The authors investigated the cell-intrinsic role of the inhibitory receptor FcγRIIB in B cell activation, plasma cell differentiation, and autoantibody generation. They used B cell-specific conditional knockout (Fcgr2b-cKO) mice, marginal zone (MZ) B cell-deficient Notch2/Fcgr2b double-knockout mice, and human samples from patients with systemic lupus erythematosus (SLE) to assess FcγRIIB expression across B cell subsets.
What was found
Loss of FcγRIIB on mouse B cells produced a spontaneous increase in autoantibody titers (most pronounced for IgG3) and an expansion of IgG3+ plasma cells and B cells in extrafollicular responses. MZ B cells exhibited the highest FcγRIIB expression in both mice and humans. Lack of FcγRIIB triggering was associated with heightened MZ B cell activation, Erk phosphorylation, and calcium flux. The heightened IgG3 response seen after immunization in Fcgr2b-cKO mice was eliminated in MZ-deficient Notch2/Fcgr2b double-knockout mice. Patients with SLE had decreased FcγRIIB expression that was most pronounced in MZ B cells. No exact numerical values or effect sizes were provided in the abstract.
Why it matters
The findings identify marginal zone B cells as a critical checkpoint where loss of FcγRIIB inhibitory signaling drives aberrant extrafollicular autoantibody responses, clarifying a mechanism underlying systemic lupus erythematosus pathology.
Limits
The abstract reports no sample sizes, numerical measurements, effect sizes, or human cohort clinical characteristics. Findings are primarily derived from mouse models, and human data are limited to ex vivo receptor expression comparisons without functional intervention.
Cited by
- supports In lupus, there is a familial mutation in a B-cell receptor that normally turns off the immune system, leading to susceptibility to autoantibodies.